Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Nov;1(2):173-184.
doi: 10.2217/mmt.14.20. Epub 2014 Dec 4.

The role of chemotherapy in the modern management of melanoma

Rebecca Jane Lee  1   2   1   2 , Noor Ul-Ain-Tariq  1   1 , Alberto Fusi  1   1 , Samantha Bowyer  1   1 , Paul Lorigan  1   2   1   2
Affiliations
Review

The role of chemotherapy in the modern management of melanoma

Rebecca Jane Lee et al. Melanoma Manag. 2014 Nov.

Abstract

The last 4 years have seen dramatic changes in the treatment of advanced melanoma, largely based on advances in targeted therapy and immunotherapy. This article examines the role of chemotherapy in the modern management of melanoma. We examine the evidence for promising new agents and discuss their position in the sequencing of treatment options for patients with advanced disease. In addition, we discuss the combination of chemotherapy with targeted treatments and immune therapies. Finally, we discuss future areas of research for ensuring that we maximize the potential of all agents available to us and identify new, effective treatments.

Keywords: advances; biochemotherapy; chemotherapy; melanoma.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure Paul Lorigan has recieved honoraria from, and serves in an advisory role to, Roche, GSK, BMS, Merck, Amgen, Celgene and Novartis. Rebecca Lee has recieved honorarium from Roche. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Similar articles

See all similar articles

Cited by

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013;63(1):11–30. - PubMed
    1. Balch CM, Gershenwald JE, Soong S-J, et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 2009;27(36):6199–6206. - PMC - PubMed
    1. Chapman PB, Hauschild A, Robert C, et al. Updated overall survival (OS) results for BRIM-3, a Phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with V600E BRAF-mutated melanoma. J. Clin. Oncol. 2012;30:8502.
    1. Hauschild A, Grob J-J, Demidov L V, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, Phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–365. - PubMed
    1. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 2012;367(18):1694–1703. - PMC - PubMed

LinkOut - more resources